XCNQ
MYND
, Last price
CAD
Name
MYND Life Sciences Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
93k
Net income
-2m
L-57.45%
CFO
-198k
L-89.10%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Kelowna, Canada, MYND Life Sciences Inc. operates as a neuro-pharmaceutical enterprise focused on creating innovative therapies for depressive disorders. The company conducts scientific research and clinical trials across Canada and the United States to develop drugs derived from neuro-anti-inflammatory compounds. A significant part of their work involves the study and development of psilocin and psilocybin extracts, as well as their synthetic analogs.
Headquarters & legal address
105-2248 ELGIN AVE PORT COQUITLAM
Coquitlam, BC V3C 2B2
CA
Coquitlam, BC V3C 2B2
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑10 | 2022‑10 | 2021‑10 | 2020‑10 | 2019‑10 | |
| Income | |||||
Revenues | |||||
Cost of revenue | |||||
Unusual Expense (Income) | |||||
NOPBT | |||||
NOPBT Margin | |||||
Operating Taxes | |||||
Tax Rate | |||||
NOPAT | |||||
Net income | |||||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | |||||
| Cash flow | |||||
Cash from operating activities | |||||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | |||||
FCF | |||||
| Balance | |||||
Cash | |||||
Long term investments | |||||
Excess cash | |||||
Stockholders' equity | |||||
Invested Capital | |||||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | |||||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | |||||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||